The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study

نویسندگان

  • Jeanne C Latourelle
  • Mei Sun
  • Mark F Lew
  • Oksana Suchowersky
  • Christine Klein
  • Lawrence I Golbe
  • Margery H Mark
  • John H Growdon
  • G Frederick Wooten
  • Ray L Watts
  • Mark Guttman
  • Brad A Racette
  • Joel S Perlmutter
  • Anwar Ahmed
  • Holly A Shill
  • Carlos Singer
  • Stefano Goldwurm
  • Gianni Pezzoli
  • Michela Zini
  • Marie H Saint-Hilaire
  • Audrey E Hendricks
  • Sally Williamson
  • Michael W Nagle
  • Jemma B Wilk
  • Tiffany Massood
  • Karen W Huskey
  • Jason M Laramie
  • Anita L DeStefano
  • Kenneth B Baker
  • Ilia Itin
  • Irene Litvan
  • Garth Nicholson
  • Alastair Corbett
  • Martha Nance
  • Edward Drasby
  • Stuart Isaacson
  • David J Burn
  • Patrick F Chinnery
  • Peter P Pramstaller
  • Jomana Al-hinti
  • Anette T Moller
  • Karen Ostergaard
  • Scott J Sherman
  • Richard Roxburgh
  • Barry Snow
  • John T Slevin
  • Franca Cambi
  • James F Gusella
  • Richard H Myers
چکیده

BACKGROUND We report age-dependent penetrance estimates for leucine-rich repeat kinase 2 (LRRK2)-related Parkinson's disease (PD) in a large sample of familial PD. The most frequently seen LRRK2 mutation, Gly2019Ser (G2019S), is associated with approximately 5 to 6% of familial PD cases and 1 to 2% of idiopathic cases, making it the most common known genetic cause of PD. Studies of the penetrance of LRRK2 mutations have produced a wide range of estimates, possibly due to differences in study design and recruitment, including in particular differences between samples of familial PD versus sporadic PD. METHODS A sample, including 903 affected and 58 unaffected members from 509 families ascertained for having two or more PD-affected members, 126 randomly ascertained PD patients and 197 controls, was screened for five different LRRK2 mutations. Penetrance was estimated in families of LRRK2 carriers with consideration of the inherent bias towards increased penetrance in a familial sample. RESULTS Thirty-one out of 509 families with multiple cases of PD (6.1%) were found to have 58 LRRK2 mutation carriers (6.4%). Twenty-nine of the 31 families had G2019S mutations while two had R1441C mutations. No mutations were identified among controls or unaffected relatives of PD cases. Nine PD-affected relatives of G2019S carriers did not carry the LRRK2 mutation themselves. At the maximum observed age range of 90 to 94 years, the unbiased estimated penetrance was 67% for G2019S families, compared with a baseline PD risk of 17% seen in the non-LRRK2-related PD families. CONCLUSION Lifetime penetrance of LRRK2 estimated in the unascertained relatives of multiplex PD families is greater than that reported in studies of sporadically ascertained LRRK2 cases, suggesting that inherited susceptibility factors may modify the penetrance of LRRK2 mutations. In addition, the presence of nine PD phenocopies in the LRRK2 families suggests that these susceptibility factors may also increase the risk of non-LRRK2-related PD. No differences in penetrance were found between men and women, suggesting that the factors that influence penetrance for LRRK2 carriers are independent of the factors which increase PD prevalence in men.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

BACKGROUND Mutations in LRRK2, the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit o...

متن کامل

P 105: The Role of LRRK2 Inhibitors in Treatment of Parkinson’s Disease

Parkinson’s disease is the second most common age associated neuron degenerative disorder in developed societies. With the prevalence ranging from 41 per 100000 in the fourth decade of life to over 1900 per 100000 in people over 80 years of age.it characterized clinically by resting tremor, slowness of movement, rigidity and postural instability in the result of progressive loss of dopami...

متن کامل

Low prevalence of most frequent pathogenic variants of six PARK genes in sporadic Parkinson's disease.

Genetic variants that confer susceptibility to Parkinson's disease (PD) show unbalanced distribution among different populations; genetic predisposition to either familial or sporadic forms of PD in Mexican-mestizo population has not been comprehensively studied. The aim of the present study was to analyze genetic variants in six PARK genes in PD patients. In total 381 individuals (173 patients...

متن کامل

Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause some forms of autosomal dominant Parkinson's disease. We measured the frequency of a novel mutation (Gly2019 ser) in familial Parkinson's disease by screening genomic DNA of patients and controls. Of 767 affected individuals from 358 multiplex families, 35 (5%) individuals were either heterozygous (34) or homozygous (one) for the ...

متن کامل

LRRK2 in Parkinson's disease – drawing the curtain of penetrance: a commentary

Parkinson's disease is the most common neurodegenerative movement disorder and affects about 2% of the population over the age of 60 years. In 2004, mutations in the LRRK2 gene were first described and turned out to be the most frequent genetic cause of familial and sporadic Parkinson's disease and may account for up to 40% of patients in distinct populations. Based on these findings, Latourell...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • BMC Medicine

دوره 6  شماره 

صفحات  -

تاریخ انتشار 2008